Smart Buying Tips,Axon

The scientific community's pursuit of effective treatments for neurodegenerative diseases, particularly Alzheimer's disease (AD), has brought compounds like Axon Peptide 108 into sharp focus. This peptide, primarily recognized for its role in the development of the AADvac1 vaccine, represents a significant advancement in neuroscience and peptide-based therapeutics. This article will explore the nature of Axon Peptide 108, its application in AADvac1, and its broader implications within the field of peptide research, drawing upon extensive data and clinical trial information.

Understanding Axon Peptide 108 and its Conjugation

Axon Peptide 108 is a specific peptide sequence, identified as N-terminally cysteinylated tau 294–305/4R, with an amino acid sequence of CKDNIKHVPGGGS. Its therapeutic potential is largely realized when it is conjugated to keyhole limpet haemocyanin (KLH). This conjugation process is crucial for enhancing the immunogenicity of the peptide, enabling it to effectively stimulate the immune system. The AADvac1 vaccine, developed by AXON Neuroscience, utilizes this conjugated form. According to study details for NCT03174886, the intervention for AADvac1 involves Axon Peptide 108 coupled to KLH in a suspension for injection. Different dosages have been explored in clinical trials, with some indicating 40 µg of Axon Peptide 108 coupled to KLH per dose, while others mention 160 µg/0.30 mL suspension for injection. The inclusion of aluminium hydroxide Al(OH)3 (containing approx. 0.5 mg) has also been noted as an adjuvant in some formulations.

AADvac1: A Promising Immunotherapy for Alzheimer's Disease

The primary application of Axon Peptide 108 is as the active component of AADvac1, an active immunotherapy designed to combat Alzheimer's disease. AXON Neuroscience has been at the forefront of this research, with AADvac1 being developed as a disease-modifying treatment for AD and other tauopathies. The vaccine works by stimulating patients' immune systems to generate specific antibodies against diseased forms of tau protein. This approach aims to target the neurodegeneration caused by the accumulation of abnormal tau protein, a hallmark of Alzheimer's disease.

Clinical trials have provided valuable insights into the safety and efficacy of AADvac1. A 24-month Phase 1 pilot study (NCT03174886) and subsequent trials like the ADAMANT trial have evaluated its performance. AADvac1 is administered as a suspension for subcutaneous injection. Positive results from these studies have indicated favorable safety profiles, strong immune responses, and supportive clinical effects, leading to its selection for landmark combination-therapy Alzheimer's clinical trials. AXON Neuroscience has presented results from its Phase II Clinical Study for AADvac1 at various scientific conferences, including Eurotau2021, highlighting its ongoing commitment to advancing this therapeutic.

Beyond Alzheimer's: The Broader Potential of Peptides in Medicine

While Axon Peptide 108 is currently most associated with Alzheimer's research, the broader field of peptide therapy is rapidly expanding. Peptides have demonstrated efficacy in various areas, including tissue healing, gut healing, and performance/longevity enhancement. The development of peptide vaccines, as exemplified by AXON Neuroscience's work, showcases the versatility of this class of molecules. AXON Neuroscience has even explored its established peptide-based vaccine platform for other applications, such as a novel prophylactic COVID-19 vaccine.

Furthermore, research into targeted axonal import (TAxI) peptides highlights the potential for peptides to deliver protein cargo into spinal cord motor neurons after intramuscular injection by a retrograde pathway. This suggests that peptides can be engineered for specific cellular delivery mechanisms, opening doors for novel drug delivery systems. The study of peptidergic nociceptive axon visualization also underscores the intricate roles peptides play in neuronal signaling and sensory pathways.

Quality and Reliability in Peptide Research

For researchers and developers working with peptides, ensuring the quality and reliability of these compounds is paramount. Platforms like AxonPeptide.com emphasize delivering independently verified research compounds supported by defined analytical methods and consistent quality standards. They offer lab-grade peptides you can trust, with independently lab tested products and full Certificates of Analysis, ensuring quick and reliable shipping. This commitment to quality is essential for reproducible scientific outcomes and the successful advancement of peptide-based therapies.

Related Entities and Concepts

The research surrounding Axon Peptide 108 and AADvac1 intersects with several other significant entities and concepts in the pharmaceutical and biomedical landscape. These include AxonNeuroscience, the company spearheading much of this development, and related clinical trial designations such as **AADvac1 phase